Candel Therapeutics, Inc. CADL Increase (decrease) in contract liabilities and current deferred income
Increase (decrease) in contract liabilities and current deferred income at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Candel Therapeutics, Inc. (CADL) reported increase (decrease) in contract liabilities and current deferred income of -$22K in Q1 2026.
- How has Candel Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income changed year-over-year?
- Candel Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income decreased by 149.4% year-over-year, from $44.5K to -$22K.
- What is the long-term trend for Candel Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Over 3 years (2021 to 2025), Candel Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income has grown at a 12.5% compound annual growth rate (CAGR), from -$125K to $178K.